169results about How to "Weak affinity" patented technology

The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an autoantibody, vectors comprising the same, compositions comprising CAAR vectors packaged in viral particles, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified T cell expressing a CAAR (CAART) wherein the expressed CAAR comprises a desmoglein extracellular domain.

The present invention relates to optimized Fc variants, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.

The present invention relates to a method of treating or preventing musculoskeletal pain in a mammal receiving administration of an estrogen. suppressant selected from the group consisting of aromatase inhibitors, GnRH analogues, cyclo-oxy-genase 2 (COX-2) inhibitors, 17β-hydroxysteroid dehydrogenase type 1 inhibitors, progestogens, anti-estrogens and combinations thereof, said method comprising the administration of an effective amount of an estrogenic component, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula (1) in which formula R₁, R₂, R₃, R₄ independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors.

Methods and compositions for treating post-surgical gastrointestinal dysfunction are provided. Methods include administering a quaternary derivative of noroxymorphone (e.g., methylnaltrexone) to a patient after a segmental colectomy is performed on the patient.

There are provided compounds of formula I,

wherein:

Y represents NR²R³;

one of R² and R³ represents —[C_2-4 alkylene-O]_1-12—[C_2-4 alkylene]-R^2a and the other of R² and R³ has a meaning given in the description; and

R, R¹, R^2a, R^a, R^b, Q, X and Y have meanings given in the description,

which compounds have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be altered in the variant polypeptide. The application also discloses a variant of a parent polypeptide comprising a human IgG Fc region, which variant has a better binding affinity for human C1q than the parent polypeptide

The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

In a glass panel arrangement for automotive sun roof systems having a weather strip frame which is disposed substantially flush with the glass panel, a support frame made of metallic material and attached to a lower surface of the glass panel along a peripheral part of the glass panel is provided with an outer extension for supporting a part of the weather strip frame extending away from the edge of the glass panel from below so as to resist the tendency for the weather strip frame to get detached from the outer periphery of the glass panel. Therefore, the weather strip frame can be made of plastic material which has a relatively low affinity with the glass panel. In particular, if the outer extension is provided with an upwardly directed flange, not only the retaining force of the outer extension is improved but also the bending rigidity of the outer extension is improved.

The invention relates to methods of targeted drug delivery of antiviral compounds, including, chemical agents (like nucleoside analogs or protease inhibitors) and nucleic acid based drugs (like DNA vaccines, antisense oligonucleotides, ribozymes, catalytic DNA (DNAzymes) or RNA molecules, siRNAs or plasmids encoding thereof). Furthermore, the invention relates to targeted drug delivery of antiviral compounds to intracellular target sites within cells, tissues and organs, in particular to target sites within the central nervous system (CNS), into and across the blood-brain barrier, by targeting to internalizing uptake receptors present on these cells, tissues and organs. Thereto, the antiviral compounds, or the pharmaceutical acceptable carrier thereof, are conjugated to ligands that facilitate the specific binding to and internalization by these receptors.

A newborn transfusion cell washing device generally comprising a disposable, graduated test tube shaped container having a cap with an inlet port, an injection/sampling port, a suction port, and a vent. The container is capable of being inserted into a conventional clinical centrifuge. The device requires a relatively small volume to operate, 25 ml or less per procedure, and can be performed easily by any hospital blood bank technologist without any special skills. Washed RBCs can be provided to the patient in a timely manner, without the need for “fresh blood.” Any in-dated RBCs can be washed to remove excessive potassium and other toxins. The main RBC aliquot can be saved and repeatedly sampled until the unit is expired or exhausted. This provides a cost savings to the hospital and more importantly, minimizes the recipient's donor exposure.

A polymer of which dissolution rate in an alkaline developer increases under the action of acid comprises recurring units having formulae (1) and (2) wherein R¹, R², and R⁴ are H or methyl, R³ is difluoromethyl or trifluoromethyl, and X is tertiary alkyl. A resist composition comprising the polymer has a high sensitivity and resolution, decreased pattern collapse during development, and minimized MEF and is best suited as micropatterning material for the VLSI manufacture.

The present invention relates to compounds having therapeutic effects against disorders in the central nervous system, and in particular substituted phenylpiperidines of the formula 1:

wherein R is as defined herein.